Opioid Addiction Solution offers affordable treatment and the end of opioid addiction at its new clinic location in Baton Rouge, Louisiana.
suboxone clinic Baton Rouge LA facility, dedicated to the end of opioid addiction through affordable treatment plans. The facility focuses on affordable treatment and relief of opioid dependency throughout Louisiana. The goal-oriented, results-driven practice provides Medication-Assisted Treatment (MAT) with buprenorphine (Suboxone®, Subutex®, and others) to assist patients to affordably overcome and end their opioid dependency without having to go through withdrawal. The patients are treated with dignity and respect, while confidentiality and discretion are assured. When necessary, OAS advocates for patients in family, legal, and employment matters.— Opioid Addiction Solution and John P. Sommer are pleased to announce the opening of the new
The menu of services available to patients and families includes outpatient treatment for opioid use disorder, outpatient treatment of opioid use disorder during pregnancy, outpatient psychiatric services, addiction counseling, both individual and group, behavioral therapy, outpatient treatment for alcohol use disorder and smoking cessation, drug testing services, and patient advocacy.
More details are available at http://opioidaddictionsolution.com
Buprenorphine is the active ingredient in Suboxone®, Subutex®, and similar drugs, is itself an opioid. Unlike opioid prescription painkillers, methadone, and heroin, which are full opioid agonists, buprenorphine is a partial opioid agonist. Buprenorphine attaches to the same receptors in the brain that other opioids attach to, but its maximal effects are less than those of full agonists. Buprenorphine produces a sufficient agonist effect to enable opioid-dependent individuals to discontinue the misuse of opioids and function generally without experiencing withdrawal symptoms, impairment, or cravings.
With appropriate dedication, motivation, counseling, and behavioral therapy, buprenorphine treatment can allow for successful tapering of dose and, ultimately, ending opioid dependence. Besides, buprenorphine has been shown to carry a lower risk of abuse, addiction, and side effects compared to full opioid agonists.
A representative of the facility stated, “A number of clinical trials have established that buprenorphine is effective for reducing the risk of overdose, alleviating symptoms of opioid withdrawal, reducing cravings for opioids, reducing opioid misuse, blocking the effects of other opioids, helping patients stay in treatment and allowing patients to regain control over their lives.”
Name: John P. Somner
Email: Send Email
Organization: Opioid Addiction Solution
Address: 7520 Perkins Road Suite 180, Baton Rouge LA
Phone: (225) 999-2265
Release ID: 88927680